Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

This study has been terminated.
Information provided by (Responsible Party):
Curis, Inc. Identifier:
First received: September 25, 2012
Last updated: June 4, 2014
Last verified: June 2014
The main purpose of this study is to determine the safety and tolerability of orally administered CUDC-101 in cancer patients, and to determine a dose for further testing. This study will also determine how well CUDC-101 is absorbed into the blood after being given orally, assess CUDC-101 blood levels and what happens to the study drug in the body, and study how the body reacts to the study drug and what effects it has on tumors. CUDC-101 has been administered to cancer patients as an intravenous (IV) infusion in other research studies, but has not been studied when given orally.

Condition Intervention Phase
Drug: CUDC-101
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors

Resource links provided by NLM:

Further study details as provided by Curis, Inc.:

Primary Outcome Measures:
  • Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose of oral CUDC-101 in subjects with advanced and refractory solid tumors [ Time Frame: 21 days (1 cycle of study treatment) ]
    The highest dose level studied at which fewer than 2 out of 6 subjects (< 33%) experience a dose limiting toxicity (DLT).

  • Assess the bioavailability (BA) of orally administered CUDC-101 [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours post-dose on the first and second day of study drug dosing. ]
    Comparison of area under the plasma concentration time curve (AUC) following intravenous and oral administrations.

  • Assess the pharmacokinetics (PK) of orally administered CUDC-101 [ Time Frame: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours post-dose on the ninth day of study drug dosing ]
    Pharmacokinetic parameters will include AUC, maximum plasma concentration (Cmax),half-life (T1/2), clearance (Cl) and volume of distribution (Vd).

Secondary Outcome Measures:
  • Assess the safety and tolerability of continuous orally administered CUDC-101 [ Time Frame: 18 months ]
    Number of participants with adverse events assessed using the NCI Common Terminology Criteria for Adverse Events (CTCAE, v4.0).

  • Evaluate biomarkers of CUDC-101 activity [ Time Frame: Day 1 and Day 7 of Cycle 1 dosing. ]
    Pre- and post-dose changes in acetylated histone H3 protein levels in peripheral blood mononuclear cells (PBMCs), as well as skin and tumor biopsy samples (where available).

  • Assess preliminary anti-cancer activity [ Time Frame: 18 months ]
    Occurrences of complete response, partial response, stable disease and progressive disease as determined by the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).

Enrollment: 3
Study Start Date: September 2012
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CUDC-101
200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
Drug: CUDC-101
200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects with a histopathologically confirmed diagnosis of advanced solid tumor.
  2. Subjects must have no further standard of care options.
  3. Measurable or non-measurable disease
  4. Age ≥ 18 years
  5. ECOG performance status ≤ 2
  6. Life expectancy ≥ 3 months
  7. Women of child bearing potential must have a negative serum pregnancy test.
  8. Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; creatinine ≤ 1.5x upper limit of normal (ULN); total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. For subjects with documented liver metastases, the AST/ALT may be ≤ 5x ULN
  9. Serum magnesium and potassium within normal limits (may be supplemented to achieve normal values).
  10. Subjects with brain metastases are eligible if controlled on a stable dose of ≤ 10mg prednisone/day or its equivalent dose of steroids.
  11. Men and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for 60 days following the last study treatment.
  12. Able to provide written informed consent and to follow protocol requirements.

Exclusion Criteria:

  1. Systemic anticancer therapy within 28 days prior to study treatment. Subjects with prostate cancer on LHRH hormonal therapy may be enrolled and continue on this therapy.
  2. Use of any investigational agent(s) within 21 days prior to study treatment.
  3. Known human immunodeficiency virus (HIV) positive, hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
  4. Subjects receiving moderate or strong CYP3A4 or CYP2D6 inhibitors within 7 days prior to study treatment (See Appendix C for examples).
  5. Serious infection requiring systemic antibiotic therapy within 14 days prior to study treatment.
  6. Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of CUDC-101.
  7. Ongoing diarrhea of any grade (per NCI CTCAE v4.03).
  8. Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
  9. Unstable or clinically significant concurrent medical condition that would, in the opinion of the Investigator, jeopardize the safety of a subject and/or their compliance with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01702285

United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
Southern Texas Accelerated Research Therapeutics
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Curis, Inc.
  More Information

Responsible Party: Curis, Inc. Identifier: NCT01702285     History of Changes
Other Study ID Numbers: CUDC-101-105
Study First Received: September 25, 2012
Last Updated: June 4, 2014

Keywords provided by Curis, Inc.:
Advanced Solid Tumors
Dose-Escalation processed this record on April 26, 2017